SCHEMBL2117372

SCHEMBL2117372

CC(=O)c1c(C=C2C(=O)Nc3ccc(Br)cc32)[nH]c(C(=O)NCCCN2CCCC2)c1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 9/20 0.56
KDR P35968 7/20 0.56
FGFR1 P11362 4/20 0.56
TLK2 Q86UE8 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.53
EGFR P00533 1/20 0.51
KIT P10721 1/20 0.46
HDAC3 O15379 2/20 0.45
HDAC4 P56524 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC7 Q8WUI4 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC10 Q969S8 2/20 0.45
HDAC11 Q96DB2 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
HDAC9 Q9UKV0 2/20 0.45
HDAC5 Q9UQL6 2/20 0.45
FLT3 P36888 3/20 0.45
CSF1R P07333 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13755186 1.00 PDGFRB (0.56) PDGFRBKDRFGFR1TLK2L3MBTL1
SCHEMBL13755221 0.96 PDGFRB (0.61) PDGFRBKDRFGFR1TLK2L3MBTL1
SCHEMBL31672485 0.96 PDGFRB (0.61) PDGFRBKDRFGFR1TLK2L3MBTL1
SCHEMBL2117256 0.96 PDGFRB (0.61) PDGFRBKDRFGFR1TLK2L3MBTL1
SCHEMBL13755220 0.93 KDR (0.58) PDGFRBKDRFGFR1TLK2L3MBTL1
SCHEMBL2118656 0.93 KDR (0.58) PDGFRBKDRFGFR1TLK2L3MBTL1
SCHEMBL31672422 0.93 KDR (0.58) PDGFRBKDRFGFR1TLK2L3MBTL1
SCHEMBL31672551 0.91 PDGFRB (0.54) PDGFRBKDRFGFR1TLK2L3MBTL1
SCHEMBL2114260 0.91 PDGFRB (0.54) PDGFRBKDRFGFR1TLK2L3MBTL1
SCHEMBL13755194 0.91 PDGFRB (0.54) PDGFRBKDRFGFR1TLK2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094998-A1 Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates NEKTAR THERAPEUTICS (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094998-A1 Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates PTK2B, ERBB2, FRK PDGFRB 555/4885KDR 395/4885FGFR1 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.